Four and a half years ago, we organized a special Xconomy biotech forum: an evening focused on what the Boston life sciences scene would look like 20 years down the road. Fast forward through a major recession, a new presidency, and further increases in healthcare costs, and the life sciences world looks much different already. So we thought it was high time to bring together some of the biggest names in the Boston biotech scene (and beyond) to discuss and revisit the changes we might expect to see in the next 20 years.
Our speakers, whom you can learn more about in this slideshow, were Deborah Dunsire, John Mendlein, Michael Bonney, Noubar Afeyan, and Dennis Ausiello. Their discussion topics included the increasing importance of big data and mobile health, the necessity of finding ways to lower the costs of developing and administering treatments, and the vitality of startups within the life sciences ecosystem.
A huge thanks to Millennium: The Takeda Oncology Company for being outstanding event hosts. A special thanks also to our event sponsors: BDO, Cubist Pharmaceuticals, Halloran Consulting Group, and Perkins + Will, as well as to our event partner, MassBio. And of course, huge thanks to KeithSpiroPhoto courtesy of Kendall PRess for the pictures. Enjoy.
Thea Bissell did the actual work of assembling this slideshow.
Gregory T. Huang is Xconomy's Deputy Editor, National IT Editor, and the Editor of Xconomy Boston. You can e-mail him at firstname.lastname@example.org.